Close Menu

bladder cancer

The firm said that adjuvant nivolumab had benefitted patients regardless of PD-L1 expression, and that the company will submit the data to regulatory agencies.

Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.

GeneCentric's RNA-based molecular profiling platform will identify relevant non-muscle invasive bladder cancer subtypes and markers for potential therapeutic options.

GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.

A study found that patients with a mutation in ARID1A and expression of immune cytokine CXCL13 had better overall survival on immune checkpoint inhibitors.

In another study at ASCO, the immunotherapy showed benefits as maintenance therapy in advanced bladder cancer patients, regardless of PD-L1 expression status.

The platform was used to subtype patients in a Phase II trial and found that patients in the claudin-low subgroup had the best two-year progression-free survival on pembrolizumab.

This is the second approval for tislelizumab following the drug's initial approval in classical Hodgkin's lymphoma last year.

The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.

The company will collaborate the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy in France, and the University Health Network in Toronto, Canada.

Pages